TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07721025: Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

Sponsor: Lexeo Therapeutics · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 26 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$8,100,800

Rescue Site Savings

+$5,345,200

Unlock Full NCT07721025 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07721025 Rescue Dossier →